Soft Tissue Sarcoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology

• DOI: 10.6004/jnccn.2016.0078
• Publication Date: 2017-04-14T16:08:25Z
• Authors: Margaret von Mehren; R. Lor Randall; Robert S. Benjamin; Sarah Boles; Marilyn M. Bui; Ernest U. Conrad; Kristen N. Ganjoo; Suzanne George; Ricardo J. Gonzalez; Martin J. Heslin; John M. Kane; Henry Koon; Joel Mayerson; Martin McCarter; Sean V. McGarry; Christian Meyer; Richard J. O'Donnell; Alberto S. Pappo; I. Benjamin Paz; Ivy A. Petersen; John D. Pfeifer; Richard F. Riedel; Scott Schuetze; Karen D. Schupak; Herbert S. Schwartz; William D. Tap; Jeffrey D. Wayne; Mary Anne Bergman; Jillian Scavone
• Keywords: 03 medical and health sciences; 0302 clinical medicine; Humans; Guidelines as Topic; Sarcoma; Medical Oncology; 3. Good health

Soft tissue sarcomas (STS) are rare solid tumors of mesenchymal cell origin that display a heterogenous mix of clinical and pathologic characteristics. STS can develop from fat, muscle, nerves, blood vessels, and other connective tissues. The evaluation and treatment of patients with STS requires a multidisciplinary team with demonstrated expertise in the management of these tumors. The complete NCCN Guidelines for Soft Tissue Sarcoma (available at NCCN.org) provide recommendations for the diagnosis, evaluation, and treatment of extremity/superficial trunk/head and neck STS, as well as intra-abdominal/retroperitoneal STS, gastrointestinal stromal tumor, desmoid tumors, and rhabdomyosarcoma. This manuscript discusses guiding principles for the diagnosis and staging of STS and evidence for treatment modalities that include surgery, radiation, chemoradiation, chemotherapy, and targeted therapy.